Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07506369
NA

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

Sponsor: University Hospital, Gentofte, Copenhagen

View on ClinicalTrials.gov

Summary

The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones. The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours: A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.

Key Details

Gender

MALE

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2026-04

Completion Date

2028-10

Last Updated

2026-04-01

Healthy Volunteers

Yes

Interventions

DRUG

Amylin (Pramlintide)

This a one of the pancreatic hormones investigated in this study. Pramlintide is used a surrogate for amylin due to the fibrillating properties of amylin

DRUG

Pancreatic Polypeptide (PP)

This a one of the pancreatic hormones investigated in this study.

DRUG

Placebo (NaCl 0.9 % solution)

This the placebo

Locations (1)

Center for Clinical Metabolic Research, Gentofte Hospital

Hellerup, Capital Region, Denmark